Stryker Co. (NYSE:SYK) Shares Sold by Creative Planning

Creative Planning lessened its stake in Stryker Co. (NYSE:SYK) by 11.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 28,210 shares of the medical technology company’s stock after selling 3,661 shares during the quarter. Creative Planning’s holdings in Stryker were worth $6,102,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of SYK. Buckingham Capital Management Inc. lifted its holdings in Stryker by 12.3% in the first quarter. Buckingham Capital Management Inc. now owns 34,399 shares of the medical technology company’s stock valued at $6,794,000 after acquiring an additional 3,769 shares during the last quarter. Bath Savings Trust Co lifted its holdings in Stryker by 5.5% in the second quarter. Bath Savings Trust Co now owns 75,254 shares of the medical technology company’s stock valued at $15,470,000 after acquiring an additional 3,946 shares during the last quarter. First Financial Bank Trust Division lifted its holdings in Stryker by 1.0% in the second quarter. First Financial Bank Trust Division now owns 48,935 shares of the medical technology company’s stock valued at $10,060,000 after acquiring an additional 496 shares during the last quarter. Private Trust Co. NA lifted its holdings in Stryker by 15.8% in the second quarter. Private Trust Co. NA now owns 21,250 shares of the medical technology company’s stock valued at $4,368,000 after acquiring an additional 2,905 shares during the last quarter. Finally, LVM Capital Management Ltd. MI lifted its stake in Stryker by 0.6% during the second quarter. LVM Capital Management Ltd. MI now owns 26,608 shares of the medical technology company’s stock worth $5,470,000 after purchasing an additional 167 shares in the last quarter. 73.13% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on SYK. Bank of America upped their price target on Stryker from $220.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Morgan Stanley upped their price target on Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 16th. BMO Capital Markets set a $216.00 price target on Stryker and gave the stock a “hold” rating in a research note on Friday, July 26th. Raymond James set a $240.00 price target on Stryker and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, Stifel Nicolaus upped their price target on Stryker from $230.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $219.08.

Shares of Stryker stock traded down $0.13 during trading hours on Friday, reaching $200.65. 391,950 shares of the company were exchanged, compared to its average volume of 1,372,875. Stryker Co. has a 1 year low of $144.75 and a 1 year high of $223.45. The stock’s fifty day moving average is $213.55 and its 200 day moving average is $205.53. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.35 and a current ratio of 2.18. The firm has a market cap of $74.21 billion, a PE ratio of 27.45, a PEG ratio of 2.43 and a beta of 0.80.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.90 by $0.01. Stryker had a return on equity of 25.33% and a net margin of 23.55%. The business had revenue of $3.59 billion for the quarter, compared to analyst estimates of $3.58 billion. During the same quarter in the prior year, the company earned $1.69 earnings per share. The company’s revenue was up 10.6% on a year-over-year basis. Research analysts expect that Stryker Co. will post 8.23 earnings per share for the current year.

In related news, VP M Kathryn Fink sold 28,690 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $220.97, for a total value of $6,339,629.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Timothy J. Scannell sold 4,666 shares of the stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $214.50, for a total value of $1,000,857.00. The disclosure for this sale can be found here. Insiders sold 67,524 shares of company stock worth $14,731,927 in the last three months. 7.20% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: Most Volatile Stocks

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply